Skip to content
Screener

Mesa Laboratories MLAB Biopharmaceutical Development — Goodwill

Other segment segments

Clinical Genomics
$17.16M+0.6%

Similar metrics at other companies

Fulgent Genetics, Inc. logo
FLGTTherapeutic Development — Goodwill
$22.35M+1.1%
BrightView Holdings, Inc. logo
BVDevelopment Services — Goodwill
$218M0.0%
nLIGHT, Inc. logo
LASRAdvanced Development — Goodwill
$10.25M0.0%
Starbucks logo
SBUXChannel Development — Goodwill
$34.7M0.0%
Newell Brands logo
NWLLearning and Development — Goodwill
$2.35B+1.4%
IQVIA logo
IQVResearch & Development Solutions — Goodwill
$3.69B+35.9%

Other financials

Income statement

See full
Revenue$60.1M+1.0%
Gross profit$31.2M-0.5%
Operating income-$664.0K+85.5%
Net income$2.8M-40.3%
EPS (diluted)-$0.10+63.0%

Balance sheet

See full
Cash & equivalents$30.7M+44.3%
Total debt$78.5M-52.9%
Total equity$188.8M+9.4%
Total assets$419.2M-3.8%

Cash flow

See full
Operating cash flow$14.7M+678%
CapEx$559.0K-44.6%
Free cash flow$14.2M+1,504%

Valuation

See full
Market cap$574.42M+72.6%
Enterprise value$622.2M+30.1%
P/E42×—
P/S2.3×+0.9×

Profitability

See full
Gross margin56.8%—
Operating margin2.3%—
Net margin1.5%+0.8pp
FCF margin21.2%+7.3pp

Returns & leverage

See full
Return on equity2.2%+1.1pp
Debt / equity0.4×-0.6×
Current ratio1.8×+1.1×

Where this comes from

Reported directly by Mesa Laboratories in its filing.

Tagged under the XBRL concept us-gaap:Goodwill.

The source filing: Mesa Laboratories’s 10-Q, filed August 10, 2026.

Filed
Aug 10, 2026, 5:17 PM EDT
Fiscal quarter
Q1 FY2027
Calendar quarter
Q2 2026
Accession
0001437749-26-026808
Line itemSterilization and Disinfection ControlBiopharmaceutical DevelopmentCalibration SolutionsClinical GenomicsTotal
March 31, 2026$82,810$49,666$37,266$17,121$186,863
Effect of foreign currency translation(273)(585)(6)39(825)
June 30, 2026$82,537$49,081$37,260$17,160$186,038

Document

FAQ

What is Mesa Laboratories's biopharmaceutical development — goodwill?
Mesa Laboratories (MLAB) reported biopharmaceutical development — goodwill of $49.08M in Q2 2026.
How has Mesa Laboratories's biopharmaceutical development — goodwill changed year-over-year?
Mesa Laboratories's biopharmaceutical development — goodwill decreased by 1.5% year-over-year, from $49.84M to $49.08M.
What is the long-term trend for Mesa Laboratories's biopharmaceutical development — goodwill?
Over 2 years (2023 to 2026), Mesa Laboratories's biopharmaceutical development — goodwill has grown at a -21.4% compound annual growth rate (CAGR), from $324.72M to $200.43M.
What does biopharmaceutical development — goodwill mean?
Represents the intangible asset value recorded when the purchase price of an acquired business within the Biopharmaceutical Development segment exceeds the fair value of its identifiable net assets. This reflects the premium paid for synergies, brand reputation, and customer relationships. Monitoring this balance is essential for assessing the long-term value of historical acquisitions.

Ask your AI about Mesa Laboratories's biopharmaceutical development — goodwill.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude